Screener
Artiva Biotherapeutics, Inc. ARTV Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Artiva Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Artiva Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338029
| Line item | SIX MONTHS ENDED JUNE 30, 2026 | SIX MONTHS ENDED JUNE 30, 2025 |
|---|---|---|
| Accounts payable (including related party amounts of $0 and $(271), respectively) | 1,032 | (168) |
| Accrued expenses (including related party amounts of $22 and $(715), respectively) | 17 | (1,481) |
| Operating lease right-of-use asset and lease liabilities, net | 241 | 21 |
| Net cash used in operating activities | (41,305) | (42,824) |
| Investing activities: | ||
| Purchases of property and equipment | (657) | (1,566) |
| Purchases of investments | (6,442) | (24,591) |
| Maturities of investments | 40,000 | 57,250 |
Item 1. Financial Statements
FAQ
- What is Artiva Biotherapeutics, Inc.'s operating cash flow?
- Artiva Biotherapeutics, Inc. (ARTV) reported operating cash flow of -$20.36M in Q2 2026.
- How has Artiva Biotherapeutics, Inc.'s operating cash flow changed year-over-year?
- Artiva Biotherapeutics, Inc.'s operating cash flow increased by 11.4% year-over-year, from -$22.98M to -$20.36M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Artiva Biotherapeutics, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude